Xarelto Lawsuit Cases In MDL Move Closer To Trial

July 02, 2016 – – TheProductLawyers.com reports on recent developments in the multidistrict litigation (MDL) No. 2592. The mass litigation against Xarelto and its manufacturers—Bayer AG and Janssen Pharmaceuticals—continues to progress towards court dates in the Eastern District of Louisiana. According to the minutes of a monthly status conference held on January 22nd, bellwether trial selections are proceeding as planned.

Originally, more than 2,800 individual lawsuits were filed, many claiming damages and undue risks associated with the new-generation anticoagulant. Following an appeal for consolidation, the U.S. Judicial Panel on Multidistrict Litigation (JPML) issued its decision to merge these and all subsequent cases brought before federal courts into MDL 2592. The JPML also appointed Judge Eldon Fallon to preside over the hearings in the Eastern District of Louisiana, in order to expedite the process. The JPML contends that this will ensure conservation of resources and time for all parties concerned, and prevent the confusion of multiple verdicts issued by different judges.

While the FDA granted its approval of Xarelto in 2011, it has since issued two black box warnings. This warning is the most severe mark against a product and precedes outright recall from the market. Initially, the new-generation anticoagulant was approved to treat those with pulmonary embolism or deep vein thrombosis, as well as serve as a clotting preventative for patients recuperating from knee or hip replacement surgeries. Almost immediately thereafter, the drug was also approved as a stroke preventative for individuals who suffered from the cardiac condition, atrial fibrillation.

However, in the years following its release, many individuals allege that the drug exposed them to a heightened risk of catastrophic bleeding events, which require extreme medical intervention and may result in lasting systemic damage. Another allegation commonly asserted is that the manufacturers were negligent, failing to warn patients and physicians adequately of the potential dangers associated with Xarelto.

Those plaintiffs represented by MDL 2592—as well as the 550 cases represented by the mass tort program scheduled consolidated by the Philadelphia Court of Common Pleas—expect that individual suits will continue to be filed as they approach finalized court dates.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60011139